RNXT
RenovoRx IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$44.40M
P/E Ratio
—
EPS
$-0.32
Beta
1.22
52W High
$1.45
52W Low
$0.70
50-Day MA
$0.95
200-Day MA
$1.06
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. The company is headquartered in Los Altos, California.
Fundamentals
| Revenue (TTM) | $1.12M |
| Gross Profit (TTM) | 796,000 |
| EBITDA | $-12.01M |
| Operating Margin | -1270.00% |
| Return on Equity | -225.60% |
| Return on Assets | -92.60% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $0.15 |
| Price-to-Book | 8.14 |
| Price-to-Sales (TTM) | 39.54 |
| EV/Revenue | 33.25 |
| EV/EBITDA | -4.72 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 453.50% |
| Shares Outstanding | $45.05M |
| Float | $40.90M |
| % Insiders | 3.77% |
| % Institutions | 14.57% |
Analyst Ratings
Consensus ($6.88 target)
4
BuyData last updated: 4/9/2026